CDR348T

**CDR348T** is a preclinical-stage therapeutic candidate developed by Cardior Pharmaceuticals for the treatment of **hypertrophic cardiomyopathy (HCM)**, a cardiovascular disease characterized by abnormal thickening of the heart muscle. It functions through **modulation of non-coding RNAs (ncRNAs)**, which play critical roles in cardiac remodeling and dysfunction, aiming to address underlying pathological mechanisms without disclosing the specific ncRNA target. Originally initiated at Hannover Medical School, the program leverages synthetic oligonucleotides to interfere with ncRNA activity, similar to Cardior's lead asset CDR132L targeting miR-132, with potential for subcutaneous administration to improve cardiac function and halt disease progression.